0
My cart

Choose your region, country/territory, and preferred language

Home Products CGMP CRISPR ManufacturingCRISPR CGMP gRNA Manufacturing

CRISPR CGMP gRNA Manufacturing Services

For customers looking to accelerate their therapeutic gene editing program from discovery to clinical trials, our Engineering run and CGMP compliant gRNA (gRNA) Manufacturing Services offer a streamlined and regulated solution. Backed by comprehensive documentation, our services simplify regulatory filings, offering a straightforward path to clinical success.

REQUEST CONSULT

Overview

Leverage advanced CRISPR technology to empower and streamline approaches to genome research. Ensure regulatory compliance through our specialized CGMP gRNA Manufacturing Services, designed to support gene editing projects. This commitment to the highest standards ensures gRNA products enhance efficiency of CRISPR genome editing projects through the therapeutic development approval process. Bring your genomic research to the forefront of personalized medicine innovation.

The IDT advantage

The IDT advantage

  • Proven excellence With over 35 years of experience, Integrated DNA Technologies (IDT) leads in oligonucleotide manufacturing, supporting your journey from research to clinical applications with unmatched expertise.
  • State-of-the-art facility Our 41,000 sq. ft. Therapeutic Oligonucleotide Manufacturing Facility delivers CRISPR CGMP gRNA grades tailored to your development—from preclinical studies to clinical trials.
  • Comprehensive quality control We prioritize quality with thorough Quality Control (QC) and analytical testing. Each CRISPR gRNA meets the highest standards of quality and consistency.
  • Regulatory support aligned to clinical phases IDT provides regulatory information tailored to your clinical phase, helping you meet requirements confidently and efficiently.
  • Dedicated expert team Your project is supported by a cross-functional team of experts committed to the success of your CRISPR therapeutics program.

Request a consultation

Start the conversation today to explore how our CGMP gRNA Manufacturing Services can accelerate your therapeutic gene editing program.

Pioneering personalized CRISPR therapy

Pioneering personalized CRISPR therapy

IDT and Aldevron partnered with the Children’s Hospital of Philadelphia (CHOP) to manufacture the world’s first mRNA-based personalized CRISPR therapy for an infant with urea cycle disorder (UCD). Delivered in just six months—three times faster than standard timelines for gene editing drug products.

Read the full story

Service details

IDT’s gRNAs produced at its Therapeutic Oligonucleotide Manufacturing Facility deliver the high-quality current Good Manufacturing Practices (CGMP) material required for successful completion of your preclinical studies and clinical trials.

Engineering run: Synthetic gRNA produced by the same manufacturing process as CGMP products but with limited Quality Assurance documentation.

CGMP: Synthetic gRNA manufactured under CGMP-certified conditions and includes full Quality Assurance Documentation.

Engineering run CGMP
Availability Delivery times after placing the order Delivery times after placing the order
Cleanroom Certification not required ISO 8 Clean Room – Certified
Changeover In-place with cleaning validation In-place with cleaning validation
Materials QA release on raw materials QA release on raw materials
Batch records Draft based on customer’s specifications Based on customer specification
Release testing Qualified methods Validated methods

Through comprehensive quality control and analytical testing, we are committed to ensure that our therapeutic oligonucleotides consistently meet the regulatory requirements to accelerate your project and bring your discoveries to life.

Category Attribute Method
Identity Molecular weight ESI-MS
Purity Purity Single-channel CE or LC-MS
Process related impurities Elemental impurities
Residual solvents
USP <233>
USP <467>
Safety Endotoxin
Bioburden
USP <85> limulus amebocyte lysate (LAL)
USP <61/62>
Yield UV/Vis Optical density at 260nm
General Appearance Visual inspection

Product data

The functional performance of 100 nt Cas9 sgRNAs targeting HPRT1 was studied using a cell-based editing activity assay in K562 cells (a human leukemia cell line) and an in vitro cleavage assay. As shown in Figure 1, pilot-run gRNAs performed better than the gRNAs with the same sequence but purified using the standard desalt method. However, similar in-cellulo % editing and in vitro % cleavage performance were observed with pilot runs and HPLC-purified gRNAs. Moreover, different pilot runs exhibited similar functional activity, demonstrating batch-to-batch consistency.
Product data

Figure 1. Functional performance of 100 nt Cas9 sgRNAs targeting HPRT1 when used in K562 CRISPR editing and in vitro DNA cleavage experiments. CRISPR editing outcomes were assessed via NGS using the rhAmpSeq™ CRISPR Analysis System following electroporation (Lonza) into K562 cells. Cas9-mediated DNA cleavage in vitro was assessed using the Fragment Analyzer system. (n = 3, error bars represent standard deviation. RUO controls were purified using either HPLC or standard desalt methods). This data is generated from pilot runs on equivalent Q7 equipment using representative Q7 manufacturing processes, methods, and tests.

Frequently asked questions

IDT offers manufacturing support for every developmental stage to meet your needs including large scale guide RNAs produced under RUO conditions, Engineering run guide RNAs that are produced by the same manufacturing process as cGMP but with limited documentation and QC, as well as cGMP guide RNAs manufactured in an ICH Q7 compliant facility.

Disclaimer

CGMP refers to products manufactured under ICHQ7; IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.